JURA Bio Secures $16.1M Seed Funding and Partners with Syena to Advance AI-Driven TCR Therapies

On September 21, 2023, JURA Bio, a biotechnology company that utilizes machine learning and synthetic biology to develop immunotherapies, announced a research collaboration with Syena, a cell therapy product company under Replay, to jointly develop T-cell receptor (TCR)-based therapies. In addition to its collaboration with Replay and Syena, JURA Bio also announced a $16.1 million financing round led by Michael Chambers, John Ballantyne, Fontus Capital, and Josh Elkington. The human immune system is a powerful source of safe and effective immune receptors; one patient may lack the TCRs necessary to fight cancer, while another may possess them.